¼¼°èÀÇ ÇǺ긮³ë°Õ ³óÃ๰ ½ÃÀå Á¶»ç º¸°í¼ : »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ ¹× ¿¹Ãø(2025-2033³â)
Global Fibrinogen Concentrates Market Research Report- Industry Analysis, Size, Share, Growth, Trends and Forecast 2025 to 2033
»óǰÄÚµå
:
1676222
¸®¼Ä¡»ç
:
Value Market Research
¹ßÇàÀÏ
:
2025³â 03¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹® 210 Pages
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¼¼°èÀÇ ÇǺ긮³ë°Õ ³óÃ๰ ½ÃÀå ±Ô¸ð´Â 2024³â 41¾ï ´Þ·¯¿¡¼ 2033³â 74¾ï ´Þ·¯¿¡ ´ÞÇϰí, 2026-2033³âÀÇ ¿¹Ãø ±â°£ µ¿¾È 6.79%ÀÇ °ß°íÇÑ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ÇǺ긮³ë°Õ ³óÃ๰ ½ÃÀåÀº ÃâÇ÷¼º ÁúȯÀÇ À¯º´·ü Áõ°¡¿Í ¼ö¼ú ¹× ¿Ü»ó ÇöÀå¿¡¼ È¿°úÀûÀÎ ÁöÇ÷Á¦¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ÈûÀÔ¾î Å« ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù. ÀÀ°í ij½ºÄÉÀ̵åÀÇ ÇÙ½É ´Ü¹éÁúÀÎ ÇǺ긮³ë°ÕÀº »óó Ä¡À¯¿Í Ç÷Àü Çü¼º¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ÀÇ·á ¼ºñ½º Á¦°ø¾÷üµéÀÌ È¯ÀÚÀÇ ¿¹Èĸ¦ °³¼±Çϰí ÃâÇ÷·Î ÀÎÇÑ ÇÕº´Áõ À§ÇèÀ» ÁÙÀ̱â À§ÇØ ³ë·ÂÇÔ¿¡ µû¶ó ÇǺ긮³ë°Õ ³óÃà Á¦Á¦ÀÇ »ç¿ëÀº Á¡Á¡ ´õ Áß¿äÇØÁö°í ÀÖ½À´Ï´Ù. ÀÌ ½ÃÀå¿¡´Â ƯÈ÷ ´ë¼ö¼ú ȯÀÚ³ª ¼±Ãµ¼º ÇǺ긮³ë°Õ °áÇÌÁõ ȯÀÚÀÇ ÁöÇ÷À» °ÈÇϱâ À§ÇØ °í¾ÈµÈ ´Ù¾çÇÑ Á¦Ç°ÀÌ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù.
±â¼úÀÇ ¹ßÀüÀº ÇǺ긮³ë°Õ ³óÃ๰ ½ÃÀåÀ» Å©°Ô Çü¼ºÇϰí ÀÖÀ¸¸ç, Á¦Á¶ °øÁ¤ ¹× Á¤Á¦ ±â¼úÀÇ Çõ½ÅÀº Á¦Ç°ÀÇ ¾ÈÀü¼º°ú È¿´ÉÀ» Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. ÷´Ü ºÐȹ¹ý°ú º´¿øÃ¼ ºñȰ¼ºÈ ±â¼úÀÇ °³¹ß·Î ÇǺ긮³ë°Õ ³óÃà Á¦Á¦ÀÇ Ç°ÁúÀÌ Çâ»óµÇ¾î ¾ö°ÝÇÑ ±ÔÁ¦ ±âÁØÀ» ÃæÁ·ÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ, ÇöÀå °Ë»ç ¹× ¸ð´ÏÅ͸µ ½Ã½ºÅÛÀÇ ÅëÇÕÀ¸·Î ÀÇ·á ¼ºñ½º Á¦°ø¾÷ü´Â ½Ç½Ã°£À¸·Î ÇǺ긮³ë°Õ ³óµµ¸¦ Æò°¡ÇÒ ¼ö ÀÖ°Ô µÇ¾î Àû½Ã¿¡ °³ÀÔÇÏ°í ¸ÂÃã Ä¡·á Á¢±Ù¹ýÀ» ½±°Ô Àû¿ëÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ½ÃÀåÀÌ °è¼Ó ÁøÈÇÔ¿¡ µû¶ó ±â¼ú Çõ½ÅÀ» ¿ì¼±½ÃÇÏ°í ¿¬±¸°³¹ß¿¡ ÅõÀÚÇÏ´Â ±â¾÷ÀÌ °æÀï¿¡¼ ¿ìÀ§¸¦ Á¡ÇÒ °¡´É¼ºÀÌ ³ô½À´Ï´Ù.
¶ÇÇÑ, ÇǺ긮³ë°Õ ³óÃ๰ ½ÃÀåÀº ´Ù¾çÇÑ ÀÇ·á¿ëµµ¿¡¼ ÇǺ긮³ë°ÕÀÇ »ç¿ëÀ» ÃËÁøÇÏ´Â ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©¿Í ÀÓ»ó °¡À̵å¶óÀÎÀÇ ¿µÇâÀ» Á¡Á¡ ´õ ¸¹ÀÌ ¹Þ°í ÀÖ½À´Ï´Ù. ÀÇ·á½Ã½ºÅÛÀÌ ±Ù°Å Á᫐ ÀǷḦ äÅÃÇÔ¿¡ µû¶ó ¾ö°ÝÇÑ ÀÓ»ó½ÃÇèÀ» ÅëÇØ ¾ÈÀü¼º°ú À¯È¿¼ºÀ» ÀÔÁõÇÑ ÇǺ긮³ë°Õ ³óÃà Á¦Á¦¿¡ ´ëÇÑ ¼ö¿ä´Â °è¼Ó Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼´Â »õ·Î¿î ¿ëµµ¸¦ ã°í ±âÁ¸ Á¦Á¦¸¦ °³¼±Çϱâ À§ÇÑ ¿¬±¸ ÀÌ´Ï¼ÅÆ¼ºê¿¡ ´ëÇÑ ÅõÀÚ¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¸ÂÃãÀÇ·á¿Í Ç¥ÀûÄ¡·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁü¿¡ µû¶ó ȯÀÚ °³°³ÀÎÀÇ ¿ä±¸¿¡ ¸Â´Â ÇǺ긮³ë°Õ ³óÃà Á¦Á¦¿¡ ´ëÇÑ ¼ö¿ä°¡ È®´ëµÉ °ÍÀ̸ç, ÀÓ»óÀû ¿ä±¸»çÇ׿¡ ºÎÇÕÇÏ´Â Á¦Á¦¸¦ Á¦°øÇÏ´Â ±â¾÷µéÀº ÀÌ Áß¿äÇÑ ½ÃÀå¿¡¼ ¼º°øÀ» °ÅµÑ ¼ö ÀÖÀ» °ÍÀÔ´Ï´Ù.
º» º¸°í¼´Â °í°´¿¡°Ô ´Ù¾çÇÑ »ê¾÷°ú ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÌ°í ½Ç¿ëÀûÀÎ ÅëÂû·ÂÀ» Á¦°øÇÒ ¼ö ÀÖµµ·Ï ¼¼½ÉÇÏ°Ô ÀÛ¼ºµÇ¾ú½À´Ï´Ù. °¢ º¸°í¼¿¡´Â ½ÃÀå »óȲÀ» ¿ÏÀüÈ÷ ÀÌÇØÇϱâ À§ÇÑ ¸î °¡Áö Áß¿äÇÑ ¿ä¼Ò°¡ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù.
½ÃÀå °³¿ä: ½ÃÀå °³¿ä: Á¤ÀÇ, ºÐ·ù, »ê¾÷ ÇöȲÀ» Æ÷ÇÔÇÑ »ó¼¼ÇÑ ½ÃÀå ¼Ò°³.
½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ: ½ÃÀå ¼ºÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÁÖ¿ä ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ¹× °úÁ¦¸¦ »ó¼¼ÇÏ°Ô ºÐ¼®ÇÕ´Ï´Ù. ÀÌ ¼½¼Ç¿¡¼´Â ±â¼ú ¹ßÀü, ±ÔÁ¦ º¯È, »õ·Î¿î Æ®·»µå µîÀÇ ¿äÀÎÀ» °ËÅäÇÕ´Ï´Ù.
¼¼ºÐÈ ºÐ¼® : Á¦Ç° À¯Çü, ¿ëµµ, ÃÖÁ¾ »ç¿ëÀÚ, Áö¿ª µîÀÇ ±âÁØ¿¡ µû¶ó ½ÃÀåÀ» ¸íÈ®ÇÑ ºÎ¹®À¸·Î ºÐ·ùÇÕ´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ °¢ ºÎ¹®ÀÇ ¼º°ú¿Í ÀáÀç·ÂÀ» ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù.
°æÀï»óȲ: ½ÃÀå Á¡À¯À², Á¦Ç° Æ÷Æ®Æú¸®¿À, Àü·«Àû ÀÌ´Ï¼ÅÆ¼ºê, À繫½ÇÀû µî ÁÖ¿ä ½ÃÀå ÁøÀÔ±â¾÷¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ Æò°¡. ÁÖ¿ä ±â¾÷µéÀÌ Ã¤ÅÃÇϰí ÀÖ´Â °æÀï ¿ªÇÐ ¹× ÁÖ¿ä Àü·«¿¡ ´ëÇÑ °íÂûÀÌ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù.
½ÃÀå ¿¹Ãø : °ú°Å µ¥ÀÌÅÍ¿Í ÇöÀç ½ÃÀå »óȲÀ» ¹ÙÅÁÀ¸·Î ÀÏÁ¤ ±â°£ µ¿¾È ½ÃÀå ±Ô¸ð¿Í ¼ºÀå Ãß¼¼¸¦ ¿¹ÃøÇÕ´Ï´Ù. ¿©±â¿¡´Â Á¤·®Àû ºÐ¼®°ú ¹Ì·¡ ½ÃÀå ±ËÀûÀ» ³ªÅ¸³»´Â ±×·¡ÇÁ Ç¥½Ã°¡ Æ÷ÇԵ˴ϴÙ.
Áö¿ª ºÐ¼® : Áö¿ªº° ½ÃÀå ¼º°ú¸¦ Æò°¡Çϰí ÁÖ¿ä ½ÃÀå ¹× Áö¿ª µ¿ÇâÀ» ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. Áö¿ª ½ÃÀå ¿ªÇÐ ¹× ºñÁî´Ï½º ±âȸ¸¦ ÀÌÇØÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù.
»õ·Î¿î Æ®·»µå¿Í ±âȸ: ÇöÀç ½ÃÀå µ¿Çâ°ú »õ·Î¿î ½ÃÀå µ¿Çâ, ±â¼ú Çõ½Å, ÀáÀçÀû ÅõÀÚ ´ë»ó ºÎ¹®À» ½Äº°ÇÕ´Ï´Ù. ¹Ì·¡ ½ÃÀå °³Ã´ ¹× ¼ºÀå Àü¸Á¿¡ ´ëÇÑ ÅëÂû·ÂÀ» Á¦°øÇÕ´Ï´Ù.
¸ñÂ÷
Á¦1Àå ¼¹®
Á¦2Àå ÁÖ¿ä ¿ä¾à
- ½ÃÀå ÇÏÀ̶óÀÌÆ®
- ¼¼°è ½ÃÀå ÇöȲ
Á¦3Àå ÇǺ긮³ë°Õ ³óÃ๰ »ê¾÷ ºÐ¼®
- ¼·Ð : ½ÃÀå ¿ªÇÐ
- ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
- ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
- ½ÃÀå ±âȸ
- »ê¾÷ µ¿Çâ
- PorterÀÇ Five Forces ºÐ¼®
- ½ÃÀåÀÇ ¸Å·Â ºÐ¼®
Á¦4Àå ¹ë·ùüÀÎ ºÐ¼®
- ¹ë·ùüÀÎ ºÐ¼®
- ¿ø·á ºÐ¼®
- ¿ø·á ¸®½ºÆ®
- ¿ø·á Á¦Á¶¾÷ü ¸®½ºÆ®
- ÁÖ¿ä ¿ø·á °¡°Ý µ¿Çâ
- ÀáÀçÀû ¹ÙÀÌ¾î ¸®½ºÆ®
- ¸¶ÄÉÆÃ Ã¤³Î
- Á÷Á¢ ¸¶ÄÉÆÃ
- °£Á¢ ¸¶ÄÉÆÃ
- ¸¶ÄÉÆÃ Ã¤³Î ¹ßÀü µ¿Çâ
Á¦5Àå ¼¼°èÀÇ ÇǺ긮³ë°Õ ³óÃ๰ ½ÃÀå ºÐ¼® : Á¦Ç° À¯Çüº°
- Á¦Ç° À¯Çüº° °³¿ä
- Á¦Ç° À¯Çüº° °ú°Å ¹× ¿¹Ãø µ¥ÀÌÅÍ ºÐ¼®
- È÷Æ®ÇǺ긮³ë°Õ ³óÃ๰
- À¯ÀüÀÚ ÀçÁ¶ÇÕ ÇǺ긮³ë°Õ ³óÃ๰
- µ¿¹° À¯·¡ ÇǺ긮³ë°Õ ³óÃ๰
- ÇÕ¼º ÇǺ긮³ë°Õ ³óÃ๰
Á¦6Àå ¼¼°èÀÇ ÇǺ긮³ë°Õ ³óÃ๰ ½ÃÀå ºÐ¼® : ¿ëµµº°
- ¿ëµµº° °³¿ä
- ¿ëµµº° °ú°Å ¹× ¿¹Ãø µ¥ÀÌÅÍ ºÐ¼®
- ¼±Ãµ¼º ÇǺ긮³ë°Õ °áÇÌÁõ
- ¿Ü°úÀû ½Ã¼ú
- ±âŸ
Á¦7Àå ¼¼°èÀÇ ÇǺ긮³ë°Õ ³óÃ๰ ½ÃÀå ºÐ¼® : ÃÖÁ¾»ç¿ëÀÚº°
- ÃÖÁ¾»ç¿ëÀÚº° °³¿ä
- ÃÖÁ¾»ç¿ëÀÚº° °ú°Å ¹× ¿¹Ãø µ¥ÀÌÅÍ ºÐ¼®
- º´¿ø
- ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)
- ±âŸ
Á¦8Àå ¼¼°èÀÇ ÇǺ긮³ë°Õ ³óÃ๰ ½ÃÀå ºÐ¼® : Áö¿ªº°
- Áö¿ªº° Àü¸Á
- ¼·Ð
- ºÏ¹ÌÀÇ ÆÇ¸Å ºÐ¼®
- °³¿ä, ºÐ¼®°ú ¿¹Ãø
- ºÏ¹Ì : ºÎ¹®º°
- ºÏ¹Ì : ±¹°¡º°
- ¹Ì±¹
- ij³ª´Ù
- ¸ß½ÃÄÚ
- À¯·´ÀÇ ÆÇ¸Å ºÐ¼®
- °³¿ä, ºÐ¼®°ú ¿¹Ãø
- À¯·´ : ºÎ¹®º°
- À¯·´ : ±¹°¡º°
- ¿µ±¹
- ÇÁ¶û½º
- µ¶ÀÏ
- ÀÌÅ»¸®¾Æ
- ·¯½Ã¾Æ
- ±âŸ À¯·´
- ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÆÇ¸Å ºÐ¼®
- °³¿ä, ºÐ¼®°ú ¿¹Ãø
- ¾Æ½Ã¾ÆÅÂÆò¾ç : ºÎ¹®º°
- ¾Æ½Ã¾ÆÅÂÆò¾ç : ±¹°¡º°
- Áß±¹
- Àεµ
- ÀϺ»
- Çѱ¹
- È£ÁÖ
- µ¿³²¾Æ½Ã¾Æ
- ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
- ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ ÆÇ¸Å ºÐ¼®
- °³¿ä, ºÐ¼®°ú ¿¹Ãø
- ¶óƾ¾Æ¸Þ¸®Ä« : ºÎ¹®º°
- ¶óƾ¾Æ¸Þ¸®Ä« : ±¹°¡º°
- ºê¶óÁú
- ¾Æ¸£ÇîÆ¼³ª
- Æä·ç
- Ä¥·¹
- ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ÆÇ¸Å ºÐ¼®
- °³¿ä, ºÐ¼®°ú ¿¹Ãø
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ºÎ¹®º°
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ±¹°¡º° ¸®½ºÆ®
- »ç¿ìµð¾Æ¶óºñ¾Æ
- ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
- À̽º¶ó¿¤
- ³²¾ÆÇÁ¸®Ä«°øÈ±¹
- ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
Á¦9Àå ÇǺ긮³ë°Õ ³óÃ๰ ±â¾÷ °æÀï ±¸µµ
- ÇǺ긮³ë°Õ ³óÃ๰ ½ÃÀå °æÀï
- Á¦ÈÞ/Çù·Â/ÇÕÀÇ
- ÀμöÇÕº´(M&A)
- ½ÅÁ¦Ç° Ãâ½Ã
- ±âŸ °³¹ß
Á¦10Àå ±â¾÷ °³¿ä
- ÁÖ¿ä ±â¾÷ÀÇ ½ÃÀå Á¡À¯À² ºÐ¼®
- ½ÃÀå ÁýÁßµµ
- Baxter International Inc
- Shanghai RAAS
- Octapharma AG
- Johnson And Johnson
- ThermoFisher Scientific
- ProFibrix BV.
- Enzo Life Sciences Inc
- CSL Behring
- GC Biopharma
- Hualan Biological Engineering Inc
LSH
¿µ¹® ¸ñÂ÷
Global Fibrinogen Concentrates Market size is anticipated to grow from USD 4.1 Billion in 2024 to USD 7.4 Billion by 2033, showcasing a robust Compound Annual Growth Rate (CAGR) of 6.79% during the forecast period of 2026 to 2033.
The Fibrinogen Concentrates market is poised for significant growth, driven by the increasing prevalence of bleeding disorders and the rising demand for effective hemostatic agents in surgical and trauma settings. Fibrinogen, a critical protein in the coagulation cascade, plays a vital role in wound healing and blood clot formation. As healthcare providers seek to improve patient outcomes and reduce the risk of complications associated with bleeding, the use of fibrinogen concentrates is becoming increasingly important. This market encompasses a range of products designed to enhance hemostasis, particularly in patients undergoing major surgeries or those with congenital fibrinogen deficiencies.
Technological advancements are significantly shaping the Fibrinogen Concentrates market, with innovations in manufacturing processes and purification techniques enhancing product safety and efficacy. The development of advanced fractionation methods and pathogen inactivation technologies is improving the quality of fibrinogen concentrates, ensuring that they meet stringent regulatory standards. Additionally, the integration of point-of-care testing and monitoring systems is enabling healthcare providers to assess fibrinogen levels in real-time, facilitating timely interventions and personalized treatment approaches. As the market continues to evolve, companies that prioritize innovation and invest in research and development will likely gain a competitive edge.
Moreover, the Fibrinogen Concentrates market is increasingly influenced by regulatory frameworks and clinical guidelines that promote the use of fibrinogen in various medical applications. As healthcare systems adopt evidence-based practices, the demand for fibrinogen concentrates that demonstrate safety and efficacy through rigorous clinical trials will continue to rise. This trend is driving investment in research initiatives aimed at exploring novel applications and improving existing formulations. As the focus on personalized medicine and targeted therapies grows, the need for fibrinogen concentrates that can be tailored to individual patient needs will expand, positioning companies that align their offerings with clinical requirements for success in this vital market.
Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:
Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.
Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.
Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.
Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.
Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.
Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.
Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.
SEGMENTATION COVERED IN THE REPORT
By Product Type
- Human Fibrinogen Concentrate
- Recombinant Fibrinogen Concentrate
- Animal-Derived Fibrinogen Concentrate
- Synthetic Fibrinogen Concentrate
By Application
- Congenital Fibrinogen Deficiency
- Surgical Procedures
- Others
By End User
- Hospitals
- Ambulatory Surgical Centers
- Others
- COMPANIES PROFILED
- Baxter International Inc
- Shanghai RAAS
- Octapharma AG
- Johnson and Johnson
- ThermoFisher Scientific
- ProFibrix BV.
- Enzo Life Sciences Inc
- CSL Behring
- GC Biopharma
- Hualan Biological Engineering Inc.
- The above list can be customized.
TABLE OF CONTENTS
1. PREFACE
- 1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
- 1.2. Research Scope
- 1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology
2. EXECUTIVE SUMMARY
- 2.1. Highlights of Market
- 2.2. Global Market Snapshot
3. FIBRINOGEN CONCENTRATES INDUSTRY ANALYSIS
- 3.1. Introduction - Market Dynamics
- 3.2. Market Drivers
- 3.3. Market Restraints
- 3.4. Opportunities
- 3.5. Industry Trends
- 3.6. Porters Five Force Analysis
- 3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Product Type
- 3.7.2 Market Attractiveness Analysis By Application
- 3.7.3 Market Attractiveness Analysis By End User
- 3.7.4 Market Attractiveness Analysis By Region
4. VALUE CHAIN ANALYSIS
- 4.1. Value Chain Analysis
- 4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
- 4.3. List of Potential Buyers
- 4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend
5. GLOBAL FIBRINOGEN CONCENTRATES MARKET ANALYSIS BY PRODUCT TYPE
- 5.1. Overview By Product Type
- 5.2. Historical and Forecast Data Analysis By Product Type
- 5.3. Human Fibrinogen Concentrate Historic and Forecast Sales By Regions
- 5.4. Recombinant Fibrinogen Concentrate Historic and Forecast Sales By Regions
- 5.5. Animal-Derived Fibrinogen Concentrate Historic and Forecast Sales By Regions
- 5.6. Synthetic Fibrinogen Concentrate Historic and Forecast Sales By Regions
6. GLOBAL FIBRINOGEN CONCENTRATES MARKET ANALYSIS BY APPLICATION
- 6.1. Overview By Application
- 6.2. Historical and Forecast Data Analysis By Application
- 6.3. Congenital Fibrinogen Deficiency Historic and Forecast Sales By Regions
- 6.4. Surgical Procedures Historic and Forecast Sales By Regions
- 6.5. Others Historic and Forecast Sales By Regions
7. GLOBAL FIBRINOGEN CONCENTRATES MARKET ANALYSIS BY END USER
- 7.1. Overview By End User
- 7.2. Historical and Forecast Data Analysis By End User
- 7.3. Hospitals Historic and Forecast Sales By Regions
- 7.4. Ambulatory Surgical Centers Historic and Forecast Sales By Regions
- 7.5. Others Historic and Forecast Sales By Regions
8. GLOBAL FIBRINOGEN CONCENTRATES MARKET ANALYSIS BY GEOGRAPHY
- 8.1. Regional Outlook
- 8.2. Introduction
- 8.3. North America Sales Analysis
- 8.3.1 Overview, Historic and Forecast Data Sales Analysis
- 8.3.2 North America By Segment Sales Analysis
- 8.3.3 North America By Country Sales Analysis
- 8.3.4 United States Sales Analysis
- 8.3.5 Canada Sales Analysis
- 8.3.6 Mexico Sales Analysis
- 8.4. Europe Sales Analysis
- 8.4.1 Overview, Historic and Forecast Data Sales Analysis
- 8.4.2 Europe By Segment Sales Analysis
- 8.4.3 Europe By Country Sales Analysis
- 8.4.4 United Kingdom Sales Analysis
- 8.4.5 France Sales Analysis
- 8.4.6 Germany Sales Analysis
- 8.4.7 Italy Sales Analysis
- 8.4.8 Russia Sales Analysis
- 8.4.9 Rest Of Europe Sales Analysis
- 8.5. Asia Pacific Sales Analysis
- 8.5.1 Overview, Historic and Forecast Data Sales Analysis
- 8.5.2 Asia Pacific By Segment Sales Analysis
- 8.5.3 Asia Pacific By Country Sales Analysis
- 8.5.4 China Sales Analysis
- 8.5.5 India Sales Analysis
- 8.5.6 Japan Sales Analysis
- 8.5.7 South Korea Sales Analysis
- 8.5.8 Australia Sales Analysis
- 8.5.9 South East Asia Sales Analysis
- 8.5.10 Rest Of Asia Pacific Sales Analysis
- 8.6. Latin America Sales Analysis
- 8.6.1 Overview, Historic and Forecast Data Sales Analysis
- 8.6.2 Latin America By Segment Sales Analysis
- 8.6.3 Latin America By Country Sales Analysis
- 8.6.4 Brazil Sales Analysis
- 8.6.5 Argentina Sales Analysis
- 8.6.6 Peru Sales Analysis
- 8.6.7 Chile Sales Analysis
- 8.6.8 Rest of Latin America Sales Analysis
- 8.7. Middle East & Africa Sales Analysis
- 8.7.1 Overview, Historic and Forecast Data Sales Analysis
- 8.7.2 Middle East & Africa By Segment Sales Analysis
- 8.7.3 Middle East & Africa By Country Sales Analysis
- 8.7.4 Saudi Arabia Sales Analysis
- 8.7.5 UAE Sales Analysis
- 8.7.6 Israel Sales Analysis
- 8.7.7 South Africa Sales Analysis
- 8.7.8 Rest Of Middle East And Africa Sales Analysis
9. COMPETITIVE LANDSCAPE OF THE FIBRINOGEN CONCENTRATES COMPANIES
- 9.1. Fibrinogen Concentrates Market Competition
- 9.2. Partnership/Collaboration/Agreement
- 9.3. Merger And Acquisitions
- 9.4. New Product Launch
- 9.5. Other Developments
10. COMPANY PROFILES OF FIBRINOGEN CONCENTRATES INDUSTRY
- 10.1. Top Companies Market Share Analysis
- 10.2. Market Concentration Rate
- 10.3. Baxter International Inc
- 10.3.1 Company Overview
- 10.3.2 Company Revenue
- 10.3.3 Products
- 10.3.4 Recent Developments
- 10.4. Shanghai RAAS
- 10.4.1 Company Overview
- 10.4.2 Company Revenue
- 10.4.3 Products
- 10.4.4 Recent Developments
- 10.5. Octapharma AG
- 10.5.1 Company Overview
- 10.5.2 Company Revenue
- 10.5.3 Products
- 10.5.4 Recent Developments
- 10.6. Johnson And Johnson
- 10.6.1 Company Overview
- 10.6.2 Company Revenue
- 10.6.3 Products
- 10.6.4 Recent Developments
- 10.7. ThermoFisher Scientific
- 10.7.1 Company Overview
- 10.7.2 Company Revenue
- 10.7.3 Products
- 10.7.4 Recent Developments
- 10.8. ProFibrix BV.
- 10.8.1 Company Overview
- 10.8.2 Company Revenue
- 10.8.3 Products
- 10.8.4 Recent Developments
- 10.9. Enzo Life Sciences Inc
- 10.9.1 Company Overview
- 10.9.2 Company Revenue
- 10.9.3 Products
- 10.9.4 Recent Developments
- 10.10. CSL Behring
- 10.10.1 Company Overview
- 10.10.2 Company Revenue
- 10.10.3 Products
- 10.10.4 Recent Developments
- 10.11. GC Biopharma
- 10.11.1 Company Overview
- 10.11.2 Company Revenue
- 10.11.3 Products
- 10.11.4 Recent Developments
- 10.12. Hualan Biological Engineering Inc
- 10.12.1 Company Overview
- 10.12.2 Company Revenue
- 10.12.3 Products
- 10.12.4 Recent Developments
Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies
°ü·ÃÀÚ·á